Actively Recruiting
Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
Led by University Hospital, Basel, Switzerland · Updated on 2023-08-22
3370
Participants Needed
1
Research Sites
343 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is to identify rare, disease-causing mutations of several rare neutrophil dermatoses. To identify associations between NMID and variants in the genome next generation sequencing, mainly whole exome sequencing, will be used. In a second approach the expression level of already known inflammatory proteins in skin samples will be investigated.
CONDITIONS
Official Title
Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written consent of the participating person
- Diagnosis of a disease in the neutrophil-mediated inflammatory dermatoses (NMID) group or being a proband in the control group
You will not qualify if you...
- Missing informed consent if samples collected after 2014 (patients)
- No diagnosis of NMID (patients)
- Missing informed consent (healthy controls)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital Basel, Clinic of Dermatology
Basel, Switzerland, 4031
Actively Recruiting
Research Team
A
Alexander Navarini, Prof. Dr. med.
CONTACT
E
Emmanuel Contassot, Dr.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here